Venous Thromboembolism
Clinical impact of anticoagulation duration determined
Published in Blood Weekly, September 29th, 2005
Patients with VTE "are susceptible to recurrent events, but whether prolonging anticoagulation is warranted in patients with VTE remains controversial," according to physicians in New York, who conducted a study to "quantify the risks and benefits of extending the duration of anticoagulation in patients with VTE."
"PubMed, EMBase Pharmacology, the Cochrane database, clinical trial Web sites, and a hand search of reference lists" were reviewed, D. Ost and coauthors at the North Shore University Hospital explained. "Included studies were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-09-29)
More Articles from Blood Weekly
- Blood Banking
Accuracy and efficacy determined for three platelet pheresis machines - Sickle Cell Anemia
Research hospital to lead trial to investigate sickle cell anemia and stroke - Stem Cell Cryopreservation
Model facilitates the cryopreservation of intact adherent hES cell colonies - Tissue Engineering
MSC and hydroxyapatite ceramic transplant treats severe osteochondral damage - Tissue Engineering
Tissue-engineered bone can be used for early stage bone regeneration - Adverse Drug Reaction
Agency discusses glucosamine and elevated cholesterol - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
